Developing a core outcome set for assessing clinical safety outcomes of cardiovascular diseases in clinical trials of integrated traditional Chinese medicine and Western medicine: study protocol
Open Access
- 28 March 2022
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-9
Abstract
Background: Integrative medicine is commonly used in China. Researchers prefer to report efficacy outcomes rather than safety outcomes in clinical trials; thus, evidence regarding safety in integrative medicine is unclear. Developing a core outcome set (COS) for safety outcomes is necessary. In this study, a representative example of the methodology for developing COS to assess safety outcomes of cardiovascular diseases in clinical trials investigating integrated medicine will be developed. Methods and analysis: Safety information will be extracted from package inserts and through systematic reviews of treatments for cardiovascular diseases (including angina pectoris, myocardial infarction, heart failure, arrhythmia, and hypertension) to develop an extensive list of safety outcomes, which will then be categorized according to whether subjective or objective outcomes. Questionnaires for clinician-reported safety outcomes and patient-reported safety outcomes will be developed. Two rounds of the Delphi survey will then be conducted for different stakeholders (traditional Chinese medicine clinicians and researchers in cardiovascular diseases, Western medicine clinicians and researchers in cardiovascular diseases, integrated medicine clinicians and researchers of cardiovascular diseases, pharmacologists, methodologists of evidence-based medicine, and patients). After round 2 of the Delphi analysis, a face-to-face consensus meeting will be held to determine the final COS for assessing safety outcomes in cardiovascular diseases. Discussion: A COS for safety outcomes in cardiovascular diseases may improve the consistency of reporting results and will help identify potential bias of selective reporting in the future. Trial registration: This study was registered in the Core Outcome Measures in Effectiveness Trials database as study 1564.Keywords
Funding Information
- National Natural Science Foundation of China (81904051)
This publication has 19 references indexed in Scilit:
- A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The BARIACT ProjectPLOS Medicine, 2016
- Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working GroupThe Journal of Rheumatology, 2016
- Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JNCI: Journal of the National Cancer Institute, 2014
- Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment TrialsJNCI: Journal of the National Cancer Institute, 2014
- Analysis of clinical safety for Shenmai injection based on literatureChina Journal of Chinese Materia Medica, 2012
- [Analysis of clinical safety for Shenmai injection based on literature].2012
- GRADE guidelines: 2. Framing the question and deciding on important outcomesJournal of Clinical Epidemiology, 2011
- Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical ConsiderationsCurrent Medicinal Chemistry, 2010
- Situation of integrative medicine in China: Results from a national survey in 2004Chinese Journal of Integrative Medicine, 2006
- Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT StatementAnnals of Internal Medicine, 2004